The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | PI3K inhibitors in r/r DLBCL
John Burke, MD, Rocky Mountain Cancer Centers, US Oncology Research, Aurora, CO, provides an overview of the PI3K inhibitor umbralisib, ublituximab, and bendamustine in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients either received umbralisib monotherapy, umbralisib and ublituximab (U2), or U2 and bendamustine, with patients on the triplet therapy receiving the best outcomes overall. The use of PI3K inhibitors in DLBCL was well tolerated overall but more research is needed to determine the role of PI3K inhibitors in treating DLBCL, especially with the approval of other treatments such as chimeric antigen receptor (CAR) T-cell therapies. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
